Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?
Pediatric Allergy and Immunology · 2025-03 · 36 (3)
DOI: 10.1111/pai.70053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 13.03.2025. Verfasst von Güler Yıldırım und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Allergy and Immunology, Cemil Taşçıoğlu City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Urticaria, Chronic Urticaria, Eosinophils. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Acute urticaria usually resolves spontaneously; however, in some cases, it may progress to CSU. We aimed to investigate the underlying factors of AU in children and the clinical and laboratory factors affecting the progression of AU to CSU.
Methods
A prospective analysis was performed in 155 patients under 18 years of age who were diagnosed with AU and treated in our hospital. Factors affecting the transition from acute urticaria to chronic urticaria were analyzed using logistic regression.
Results
Progression of AU to CSU was observed in 9% of patients. The urticaria activity scores of the first week (UAS7) in patients who progressed to CSU were significantly higher than those of patients who did not develop CSU (UAS7: Median 14.5, Min–Max 6–32, p < .001). Additionally, elevated eosinophil levels (Median 3.6%, Min–Max 0–11, p = .006) and the need for more intensive treatments, including parenteral steroids, antihistamines, and additional therapies (42.9% of CU patients, p = .038), were identified as significant risk factors for progression to CSU. In univariate regression analysis, the UAS7 score was found to be statistically significant (OR: 1.131, 95% CI: 1.056–1.212, p < .001). In multivariate analysis, we found that high UAS7 scores (OR: 1.169, 95% CI: 1.072–1.275, p < .001) and the need for combined treatment with additional therapies (OR: 8.240, 95% CI: 1.007–67.441, p = .049) were independent risk factors for progression from AU urticaria to CU.
Conclusion
We found that the severity of urticaria during the first week and the need for additional therapies are important indicators in predicting the risk of chronicity. These findings may help to develop strategies to effectively manage AU in the early stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Allergy and Immunology, Cemil Taşçıoğlu City Hospital, Istanbul, Turkey.
- Department of Pediatric Emergency, Cemil Taşçıoğlu City Hospital, Istanbul, Turkey.
- Department of Pediatric Allergy and Immunology, İstanbul University Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
- Department of Pediatric Allergy and Immunology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
ORCID-Profile: Güler Yıldırım, Deniz Ozceker, Alper Kaçar, Esra Özek Yücel, Zeynep Ülker Altınel
Zitieren
APA
Yıldırım, G., Ozceker, D., Kaçar, A., Yücel, E. Ö., & Altınel, Z. Ü. (2025). Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?. Pediatric Allergy and Immunology, 36(3). https://doi.org/10.1111/pai.70053
Vancouver
Yıldırım G, Ozceker D, Kaçar A, Yücel EÖ, Altınel ZÜ. Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?. Pediatric Allergy and Immunology. 2025;36(3). doi:10.1111/pai.70053
BibTeX
@article{Yldrm2025,
author = {Yıldırım, Güler and Ozceker, Deniz and Kaçar, Alper and Yücel, Esra Özek and Altınel, Zeynep Ülker},
title = {Can urticaria severity be used as a biomarker for transition from acute to chronic urticaria?},
journal = {Pediatric Allergy and Immunology},
year = {2025},
volume = {36},
number = {3},
doi = {10.1111/pai.70053}
}
EUVIMED